{"brief_title": "Evaluation of the Bioavailability of Pramlintide", "brief_summary": "This is a randomized, open-label, crossover study to examine the bioavailability of pramlintide in normal weight and overweight subjects with type 1 and type 2 diabetes mellitus using insulin.", "condition": ["Diabetes Mellitus, Type 1", "Diabetes Mellitus, Type 2"], "intervention_type": ["Drug"], "intervention_name": ["Pramlintide acetate"], "description": ["Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection."], "arm_group_label": ["Pramlintide acetate (AC137) injection"], "other_name": ["Symlin (pramlintide acetate)"], "criteria": "Inclusion Criteria: - HbA1c value between 6-12% - BMI <= 27 kg/m2 or BMI >=30 to <= 45 kg/m2 - Consistent insulin regimen for 2 months prior to screening", "gender": "All", "minimum_age": "18 Years", "maximum_age": "70 Years", "healthy_volunteers": "No", "mesh_term": ["Diabetes Mellitus", "Diabetes Mellitus, Type 2", "Diabetes Mellitus, Type 1", "Pramlintide", "Islet Amyloid Polypeptide"], "id": "NCT00042471"}